Newcastle innovator LightOx makes new breakthroughs in mouth cancer treatment

Source: www.business-live.co.uk Author: Coreena Ford, Chronicle and Journal business writer A Newcastle company says it has made breakthroughs in the treatment of early-stage mouth cancers on the back of an Innovate UK funding programme. Based in Newcastle city centre, LightOx uses technologies to develop light-activated treatment that can improve outcomes for patients and reduce the need for surgery. As well as a drug development arm, the company has a research tools business that sells products for research purposes. With funding from Analysis for Innovators (A4I), a grant funding programme run by Innovate UK, the UK’s innovation agency, the company is developing new light-activated chemotherapy for the treatment of early-stage oral cancer. It is the first of its kind in the UK and is currently completing pre-clinical testing. The company’s new class of light-activated chemotherapy should be administered by dentists or trained clinicians, who will apply a gel to the affected area and activate the drug with light. LightOx directors say the ground-breaking treatment is quick, simple and involves fewer side effects than surgery. They say the non-invasive treatment also significantly improves the overall patient experience, and has the potential to revolutionise light-based therapeutic markets globally. It lacked the research and development expertise to explore its potential further, and with help from A4I and its large network of partner organisations, the firm worked with Oxford-based Central Laser Facility (CLF), an institution of the Science and Technology Facilities Council, which gave the LightOx team access to its expertise and an unparalleled range [...]

Cancer drug for photoimmunotherapy approved: Japan approves drug used in new treatment

Source: www3.nhk.or.jp Author: press release A drug for a new cancer treatment called photoimmunotherapy has been granted government approval for the first time. Japan's government approved the drug last week to treat head and neck cancers, which are difficult to treat with other methods. US National Institutes of Health researcher Kobayashi Hisataka, who created the method, and Rakuten Medical, which developed the drug, held a news conference in Tokyo on Tuesday. Photoimmunotherapy involves a combination of a drug that uses antibodies to target cancer cells and chemicals that react to light. The drug is administered intravenously, and is activated when the patient's body is illuminated with near-infrared laser light, killing cancer cells. Kobayashi said he's overjoyed that the method he's been engaged in for decades was approved in Japan, and hopes it will be another option for cancer treatment. Rakuten Medical Chairman Mikitani Hiroshi said he believes the method can be combined with chemotherapy, and hopes to use it to treat patients as soon as possible. Procedures are to be carried out so that use of the drug is covered by insurance. Since the drug was approved quickly, its safety and effectiveness will continue to be assessed after it goes onto the market.

2020-09-30T05:30:04-07:00September, 2020|Oral Cancer News|

Towards the early detection of oral cancers

Source: pursuit.unimelb.edu.au Authors: Dr Tami Yap and Professor Michael McCullough, University of Melbourne If you noticed a new dark spot on your shoulder or changes in an old mole – you would know to get it checked out. But would you know if you had a skin cancer in your mouth? As our population ages, the diagnosis of oral cancer is increasing. Globally, this devastating cancer affects 750,000 people and has a five-year mortality rate of approximately 50 per cent if not detected and treated early. The insidious nature of oral cancer means it is often detected at a later stage; up to half of people who are diagnosed with oral cancer have large tumours as oral cancer is often painless and unseen. A further challenge is the limited tools to detect and monitor potential oral cancers and skin lesions over time; this forces clinicians to remove suspicious lesions by scalpel biopsy and assess pathology. A new research project aims to identify individuals who are likely to develop oral cancer, without invasive biopsies. The Melbourne University Dental School has partnered with Victorian company OptiScan, to improve screening and early diagnosis of oral cancer. The project is led by our team at the Melbourne Dental School and uses Optiscan’s state-of-the-art confocal laser endomicroscope (CLE). Known as InVivage ™, the hand-held microscope uses a laser light and confocal optics to painlessly perform “digital biopsies”. THE TECHNOLOGY OF CANCER DETECTION Oral cancer can have a devastating impact on a person’s life – removing [...]

Cell by cell in focus

Source: www.biophotonics.world Author: Sven Döring Progress can be measured in two steps in Tobias Meyer's laser laboratory and can be seen at a glance. In the background is a silver trolley, on top of it two black boxes and a monitor. The matt black compact device on the optical table in front of it is not even a fourth of it in site. Two Medicars, version 2015 and version 2019: a compact microscope for rapid cancer diagnosis during surgery. "Good news from German cancer research" was the announcement by the German government in August 2019, referring to the "precision through laser light" with which the microscope researched at Leibniz IPHT makes cancerous tissue visible, enabling surgeons to remove tumors even more precisely in the future. The black box contains a light-based tool that can be used to examine the chemical and morphological composition of the tissue. This information is evaluated with artificial intelligence and immediately indicates whether the tumor has been completely removed – in other words, whether the operation was successful. Tobias Meyer and his team from Leibniz IPHT, Friedrich Schiller University Jena, Jena University Hospital and the Fraunhofer Institute for Applied Optics and Precision Engineering are already continuing their research. They are combining the imaging procedure with a minimally invasive surgical precision tool: for laser-based microsurgery – and a new way to treat cancer in a gentle way. "Our vision," as Scientific Director Jürgen Popp describes it, "is to use light not only to identify the tumor, but [...]

Light therapy could prevent cancer treatment-related oral mucositis

Source: www.healio.com Author: Jennifer Southall Light therapy appeared to be an effective intervention for the prevention of painful oral mucositis associated with cancer treatment, according to results of a systematic review and meta-analysis. “Many patients [with cancer] can now benefit from this treatment,” Praveen R. Arany, DDS, PhD, assistant professor of oral biology and biomedical engineering at University at Buffalo School of Dental Medicine, said in a press release. “The staggering breadth of clinical application for photobiomodulation therapy, or light therapy, has been both a boon and a bane for the field. Several anecdotal clinical reports have been plagued with questionable rationales and inconsistent outcomes, often relegating this treatment to a pseudoscience.” Arany and colleagues systematically reviewed published literature in an effort to update the evidence-based clinical practice guidelines on the use of photobiomodulation — including laser and other light therapies — for the prevention and treatment of oral mucositis among patients with cancer. Patients underwent treatment with hematopoietic stem cell transplantation, head and neck radiotherapy, or head and neck radiotherapy plus chemotherapy. Study findings supported the use of photobiomodulation therapy for the prevention of oral mucositis among certain patients with cancer. HemOnc Today spoke with Arany about the research and the clinical implications of the findings. Question: What prompted this research? Answer: The current forms of cancer treatment are all essential to reduce cancer burden. Unfortunately, complications from these treatments include oral mucositis pain. This not only has a significant impact on quality of life, but also often requires [...]

2019-09-07T07:38:49-07:00September, 2019|Oral Cancer News|

New “soft” laser treatment to improve quality of life for cancer patients

Source: www.world-first.co.uk Author: staff A new "soft" laser therapy is to be used nationwide to help prevent patients undergoing treatment for neck and head cancer from suffering severe side effects. The low-level laser therapy (LLLT), or photomedicine, will help prevent patients suffering from soreness in the mouth and throat, dry mouth and swallowing problems. More than 90% of the 4,000 people a year in England and Wales who receive chemoradiotherapy for head and neck cancer experience side effects which can lead to hospital admissions and, in some cases, interrupt the course of radiotherapy. The new treatment, developed by the NHS foundation trusts of University Hospital Southampton and Newcastle Upon Tyne Hospitals, is being trialled nationwide as part of a £1.2 million study funded by the National Institute for Health Research (NIHR). One of the main complications of current treatments is oral mucositis (OM), which affects taste and speech. It causes excessive secretions of saliva, which result in nausea, vomiting and weight loss. Currently, patients are treated with a combination of painkillers and anti-sickness drugs and many require frequent hospital appointments to control their symptoms. Some also need nutritional support through nasal or stomach feeding tubes. LLLT is a drug-free treatment that stimulates damaged cells using a low energy laser beam to reduce pain and inflammation. It's more commonly used to treat musculoskeletal problems such as tendon, bone and nerve damage. Consultant clinical oncologist at Southampton General Hospital Dr Shanmugasundaram Ramkumar said the LLLT would improve quality of life for patients. [...]

Plasmonic nanobubbles can detect and kill only cancer cells

Source: www.azonano.com Author: staff The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells — often by blowing them apart — without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors. The work was conducted by researchers from Rice, the University of Texas MD Anderson Cancer Center and Northeastern University. “We address aggressive cancers that cannot be efficiently and safely treated today,” said Rice scientist Dmitri Lapotko, the study’s lead investigator. “Surgeons often cannot fully remove tumors that are intertwined with important organs. Chemotherapy and radiation are commonly used to treat the residual portions of these tumors, but some tumors become resistant to chemoradiation. Quadrapeutics steps up when standard treatments fail. At the same time, quadrapeutics complements current approaches instead of replacing them.” Lapotko said quadrapeutics differs from other developmental cancer treatments in that it radically amplifies the intracellular effect of drugs and radiation only in cancer cells. The quadrapeutic effects are achieved by mechanical events — tiny, remotely triggered nano-explosions called “plasmonic nanobubbles.” Plasmonic nanobubbles are non-stationary vapors that expand and burst inside cancer cells in nanoseconds in response to a short, low-energy laser pulse. Plasmonic nanobubbles act as a “mechanical drug” against cancer cells that cannot be surgically removed and are otherwise resistant to [...]

Detecting cancer’s biochemical ‘fingerprint’ for early diagnosis

Source: www.siliconrepublic.com Author: Claire O'Connell Detecting cancer in its early stages could help to make treatment more effective. Claire O’Connell found out from Dr Fiona Lyng about Cervassist, an emerging technology that uses spectroscopy to analyse tissue samples and spot when cells are showing signs of abnormality. So far the technology has been focusing on assessing cervical smear samples, which are routinely collected as part of screening programmes for cervical cancer in many countries. Cervical cancer is the one of the most common female cancers in Europe, and women are encouraged to be screened every few years. Cells are removed from the neck of the womb, and they are examined by eye under a microscope. If there are abnormal or potentially cancerous cells in the sample, the person can be monitored or treated as appropriate. Cervassist, which is being developed at Dublin Institute of Technology (DIT), could offer another view of those cells on the microscope slide. By shining laser light on the samples and collecting some of the scattered radiation, the technology can automatically analyse the biochemical content of the cells, explains Lyng, who is manager of the DIT Centre for Radiation and Environmental Science. "We use Raman spectroscopy to analyse the cervical samples – it's a vibrational spectroscopic technique that gives a biochemical fingerprint of a sample," she says. "If you shine laser light on a sample, light is scattered back and we collect the inelastic scatter, which contains information about the biochemical components in the sample, the [...]

2013-02-11T22:31:03-07:00February, 2013|Oral Cancer News|

Photodynamic therapy targets oral dysplasia, oral bacteria

Source: www.drbicuspid.com Author: Kathy Kincade, Editor in Chief Imagine being able to treat a suspicious lesion on a patient's tongue simply by applying a topical agent, waiting a few minutes, then exposing it to light from a handheld laser or light-emitting diode (LED) device. Imagine being able to treat bacterial and fungal infections in the oral cavity, even periodontal disease, using this same approach. That is the promise of photodynamic therapy (PDT), a minimally invasive technique that first came into medicine in the early 1900s and has been used to treat a plethora of medical conditions, including skin diseases, localized infections, age-related macular degeneration, and premalignant and malignant disorders. "PDT in the oral cavity would utilize a photosensitizing compound and a light source to activate the compound," explained Thomas Mang, PhD, research director in the Laser and Lightwave Research Center at the University at Buffalo School of Dental Medicine. "Traditionally, it has been used in head and neck lesions and oral lesions with a photosensitizer given intravenously. But in applications related to early oral lesions and those involving candida and oral species that may be involved with periodontal disease, we look to apply it topically." Distinct advantages Mang has been investigating PDT disinfection of oral biofilm and previously was involved with the development of PDT for treating cutaneous and other cancers while at Roswell Park Cancer Institute. He sees a bright future for PDT in dentistry, providing more selectivity and flexibility when treating patients with early oral lesions and microbial [...]

Handheld probe shows promise for oral cancer detection

Source: phys.org Author: staff A team of American researchers have created a portable, miniature microscope in the hope of reducing the time taken to diagnose oral cancer. The probe, which is around 20 cm long and 1 cm wide at its tip, could be used by doctors to diagnose oral cancer in real-time or as a surgical guidance tool; dentists could also use it to screen for early-stage cancer cells. The probe has been presented today in IOP Publishing's Journal of Micromechanics and Microengineering, and has shown good agreement with images of oral cancers obtained using conventional, much slower techniques at the University of Texas Health Science Centre at San Antonio, TX. Historically, the death rate associated with oral cancer is particularly high; not because it is hard to discover or diagnose, but due to the cancer being routinely discovered late in its development. Lead author of the study Dr John X J Zhang at the University of Texas at Austin said: "Today, that statement is still true, as there isn't a comprehensive programme in the US to opportunistically screen for the disease; without that, late stage discovery is more common." The probe uses a laser to illuminate areas of the sample and can view beneath the surface of tissue, creating full 3D images. It can also take a series of images and layer them on top of each other, much like the tiling of a mosaic, giving a large overall field-of-view. The key component of the probe is [...]

Go to Top